Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
August 04, 2022 16:05 ET
|
Relay Therapeutics, Inc.
Appointment of Sekar Kathiresan, M.D., CEO of Verve Therapeutics, to board of directors Disclosed three new programs from a growing breast cancer portfolio and a regulatory update on RLY-4008 at June...
Relay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate Highlights
July 28, 2022 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event
June 27, 2022 06:00 ET
|
Relay Therapeutics, Inc.
End-of-phase 1 meeting with the U.S. Food and Drug Administration (FDA) resulted in alignment on the design of a single arm trial for pan-FGFR (FGFRi) treatment-naïve FGFR2-fusion cholangiocarcinoma...
Relay Therapeutics Announces Timing of Virtual Analyst and Investor Event
June 16, 2022 07:30 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., June 16, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
May 26, 2022 07:30 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month at the Cowen 3rd Annual Oncology Innovation...
Relay Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights
May 05, 2022 16:05 ET
|
Relay Therapeutics, Inc.
Initiated the fulvestrant combination arm of the first-in-human trial for RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor, and continued to enroll patients in the single agent arm ...
Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Healthcare Conference
May 03, 2022 07:30 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Bank of America Securities 2022 Healthcare Conference...
Relay Therapeutics to Announce First Quarter 2022 Financial Results and Corporate Highlights
April 28, 2022 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
February 24, 2022 16:05 ET
|
Relay Therapeutics, Inc.
Announced RLY-4008 interim clinical data that suggest it is the first investigational therapy that selectively binds to FGFR2 and avoids off-isoform toxicities in the treatment of patients with...
Relay Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
February 17, 2022 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...